How to make digital adoption a smooth journey

Four big pharma experts explain the challenges companies face in adopting digital tech and what trends are likely to drive digital commercial strategies in the next few years.

Novo’s new oral GLP-1 Rybelsus still has obstacles to overco...

The Pharma Comms Impact Conference - For Internal & External

20 Pharmaceutical Communications Senior Speakers, 1 Day

Novo and Sanofi make case for hypo-reducing insulins at EASD

Novo Nordisk and Sanofi have gone head-to-head at this week’s European diabetes conference, with the two arch rivals trying to make the case for their competing insulins and their ability t

Novo Nordisk faces $1.8 billion lawsuit over US insulin sale...

Novo Nordisk is facing a lawsuit from disgruntled investors seeking around $1.8 billion in compensation, saying the company failed to properly update the market about the situation regardin

Novo extends R&D alliance with AI specialist e-Therapeutics